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Background: The role of recombinant activated protein C (aPC) during sepsis is still controversial. It showed anti-
inflammatory effect and improved the microvascular perfusion in experimental models of septic shock. The present study
was aimed at testing the hypothesis that recombinant aPC therapy improves the microcirculation during severe sepsis.
Methods: Prospective observational study on patients admitted in a 12-beds intensive care unit of a university hospital
from July 2010 to December 2011, with severe sepsis and at least two sepsis-induced organ failures occurring within
48 hours from the onset of sepsis, who received an infusion of aPC (24 mcg/kg/h for 96 hours) (aPC group). Patients
with contraindications to aPC administration were also monitored (no-aPC group).
At baseline (before starting aPC infusion, T0), after 24 hours (T1a), 48 hours (T1b), 72 hours (T1c) and 6 hours after the
end of aPC infusion (T2), general clinical and hemodynamic parameters were collected and the sublingual
microcirculation was evaluated with sidestream dark-field imaging. Total vessel density (TVD), perfused vessel density
(PVD), De Backer score, microvascular flow index (MFIs), the proportion of perfused vessels (PPV) and the flow
heterogeneity index (HI) were calculated for small vessels. The perfused boundary region (PBR) was measured as an
index of glycocalyx damage. Variables were compared between time points and groups using non parametric or
parametric statistical tests, as appropriate.
Results: In the 13 aPC patients mean arterial pressure (MAP), base excess, lactate, PaO2/FiO2 and the Sequential Organ
Failure Assessment (SOFA) score significantly improved over time, while CI and ITBVI did not change. MFIs, TVD, PVD,
PPV significantly increased over time and the HI decreased (p < 0.05 in all cases), while the PBR did not change. No-aPC
patients (n = 9) did not show any change in the microcirculation over time. A positive correlation was found between
MFIs and MAP. TVD, PVD and De Backer score negatively correlated with norepinephrine dose, and the SOFA score
negatively correlated with MFIs, TVD and PVD.
Conclusions: aPC significantly improves the microcirculation in patients with severe sepsis/septic shock.
Trial registration: NCT01806428Background
Sepsis is a major problem in intensive care units (ICU),
with high incidence and mortality rate [1]. Although
many studies have been conducted in order to find an
effective therapy, the treatment for such a complex syn-
drome is still a source of investigation, mainly due to the* Correspondence: a.donati@univpm.it
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reproduction in any medium, provided the oruncertainty about its pathophysiology. According to the
current hypothesis, microcirculatory alterations may con-
tribute to the defect in oxygen extraction during sepsis
and play a major role in the progression to multiorgan
dysfunction [2]. For this reason the microcirculation may
represent the best target for therapy aimed to improve
organ dysfunction and outcome. Recombinant activated
protein C (aPC) had been approved for the treatment of
patients with severe sepsis in 2001, after the PROWESS
Study showed that it was able to significantly reduce mor-
tality [3]. Unfortunately, these results were not confirmed
[4] and the drug was withdrawn from the market ten yearsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a controversial issue and papers stressing its benefits con-
tinue to be published [5-7]. APC is an endogen protein
with anti-inflammatory, anticoagulant and profibrinolitic
properties; it showed to inhibit the generation of thrombin
by inactivating factor Va and factor VIIIa [8] and this
was thought to be the most important mechanism for its
therapeutic action in sepsis. Then this theory was aban-
doned as its anti-inflammatory action seemed to be of
major relevance: preclinical studies demonstrated a host
of beneficial effects targeting NF-kB pathway [9] together
with the ability to reduce the apoptosis and decrease
citonecrosis during sepsis [10]. Moreover aPC can influ-
ence the endothelial cell function, by inhibiting white
blood cells rolling and adhesion [11], preventing the acti-
vation of inducible nitric oxide synthase (iNOS) [12]
and exerting a protective role towards the endothelial
glycocalyx [13]. Several experimental studies showed that
aPC may integratively improve the microvascular perfu-
sion during sepsis [14-17]. Only one study was conducted
so far on severely septic patients in order to translate these
experimental evidences into a clinical setting [18].
The aim of the present study was to evaluate the effect
of aPC infusion on the microcirculation in patients with
severe sepsis/septic shock.
Methods
The study was approved by the Ethics Committee of AOU
“Ospedali Riuniti Umberto I–Lancisi–Salesi” of Ancona
(Italy) and informed consent was obtained from the pa-
tients or their relatives.Patient population
This prospective observational study was conducted in a 12-
beds ICU of “Azienda Ospedaliera-Universitaria–Ospedali
Riuniti: Umberto I–Lancisi–Salesi” of Ancona (Italy) from
July 2010 to December 2011 and included patients who re-
ceived an aPC infusion (24 mcg/kg/hr for 96 hrs) for the
presence of severe sepsis/ septic shock and at least two
sepsis-induced organ failures within 48 hours of the onset
of sepsis, with no contraindications to aPC treatment (re-
cent head trauma or intracranial bleeding). Exclusion cri-
teria were: hematologic or advanced malignancies, liver
cirrhosis, severely impaired consciousness (Glasgow Coma
Scale score <7), and therapeutic limitations (do-not-resus-
citate orders).
The sample size was calculated on the Microvascular
Flow Index (MFI): 13 patients proved to be sufficient to
demonstrate a change in MFI of 0.5 (standard deviation =
0.5) with a power of 90% and an alpha error of 0.05.
During the same study period, the microcirculation was
monitored also in those patients who met the inclusion cri-
teria but did not receive aPC because of contraindications(recent head trauma or intracranial bleeding) (no-aPC
group).
General management
All patients were sedated (propofol 2–4 mg/kg/h or
midazolam 0.1–0.3 mg/kg/h and sufentanil 0.15–2 μg/kg/h
or remifentanil 1.2–4.8 μg/kg/h), intubated and mechanic-
ally ventilated. All patients were equipped with a central
venous catheter and a femoral artery catheter and
hemodynamic parameters were monitored using the
PiCCO system (Pulsion, Munich, Germany). Fluids (crys-
talloids and colloids), vasopressors (norepinephrine) and
inotropic agents (dobutamine) were provided according to
individual needs, in order to maintain the Intrathoracic
Blood Volume Index (ITBVI) within the range of normality
(800–1000 ml/m2), a normal cardiac index value, and
mean arterial pressure (MAP) > 65 mmHg.
Measurements
The Acute Physiology and Chronic Health Evaluation
(APACHE) II score [19] was obtained on the day of the
inclusion. Temperature (T), heart rate (HR), MAP and
complete hemodynamic assessment were obtained in all
patients before starting aPC infusion (T0), at 24 hours
(±3 hrs) (T1a), 48 hours (±3 hrs) (T1b), 72 hours
(±3 hrs) (T1c) and finally 6 hours (±3 hrs) after the end
of aPC infusion (T2). Arterial blood samples were with-
drawn simultaneously in order to measure blood gases,
hemoglobin, and lactate levels (Omni Roche Diagnostic,
Monza, Italy). Results of routine biological blood sam-
ples were collected and The Sequential Organ Failure
Assessment (SOFA) score [20] was calculated daily up to
day 5. Patients who did not receive aPC infusion were
monitored at the same time points.
Microcirculatory evaluation and analysis
The sublingual microcirculation was evaluated using side-
stream dark field (SDF) imaging (Microscan, Microvision
Medical, Amsterdam, the Netherlands) by an investigator
blinded to the patient’s group at the five time points previ-
ously described (T0, T1a, T1b, T1c and T2). SDF tech-
nique is described in detail elsewhere [21]. After removal
of saliva and other secretions with a gauze, the device was
gently applied without pressure to the lateral side of the
tongue, in an area approximately 1.5–4 cm from the tip of
the tongue. Five different microcirculatory sites (at least
10 sec/site) were recorded at each time point with ad-
equate focus and contrast and every effort was made to
avoid movement and pressure artifacts. A random number
was assigned to each sequence; poor-quality images were
discarded and three images for each time point were
selected and analyzed using a computer software package
(Automated Vascular Analysis Software, Microvision Med-
ical BV, Amsterdam, the Netherlands). According to the
Table 1 Demographic data of aPC and no-aPC patients
aPC group
(n = 13)
No-aPC
group (n = 9)
p
Gender Male: Female 10:3 5:4 ns
Age Median (min-max) 54 (31–77) 61 (34–84) ns
APACHE IIa Median (min-max) 26 (16–40) 29 (20–36) ns
28-day mortality Survivors 8 5 ns
Non-survivors 5 4 ns
Baseline disease Trauma 5 3 ns
COPDb 1 1 ns
Pneumonia 2 1 ns
Tiroidectomy 1 - ns
Septic shock 4 2 ns
AAAc - 1 ns
Source of sepsis Lung 5 4 ns
Urinary tract 2 1 ns
Abdomen 3 2 ns
Blood 3 2 ns
Pathogen Gram - 9 7 ns
Gram + 4 2 ns
aAcute Physiology and Chronic Health Evaluation II score.
bChronic Obstructive Pulmonary Disease.
cAbdominal Aortic Aneurismectomy.
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microcirculation using SDF imaging [22], Total Vessel
Density (TVD), Perfused Vessel Density (PVD) and De
Backer score were calculated, providing index of micro-
vascular vessel density; the Proportion of Perfused Vessels
(PPV) and the Microvascular Flow Index (MFI), reflecting
microcirculatory blood flow velocity, were analyzed semi-
quantitatively in small- (diameter < 20 μm) (MFIs) and
medium-sized vessels (20–100 μm), as described previously
[23]. The Flow Heterogeneity Index (HI) was also calcu-
lated, providing an index of heterogeneous microcirculatory
perfusion, which is common during sepsis [24]. Each se-
quence was analyzed by two investigators, both blinded to
the origin of the clip: one investigator from AOU Ospedali
Riuniti (Ancona, Italy) and the other from Academic Med-
ical Center (Amsterdam, the Netherlands). Inter-observer
variability was calculated for all the sequences analyzed: the
coefficient of variability ranged from 4.5% to 8.7% for MFI,
from 3.5% to 5.7% for the TVD and from 4.3% to 7.9% for
the PPV.
Microvascular glycocalyx assessment
SDF videos of at least 40 consecutive frames of approxi-
mately 950 μm by 700 μm sublingual tissue surface area
were analyzed using the software GlycoCheck ICU
(Maastricht University Medical Center, Maastricht, The
Netherlands) in order to measure the Perfused Bound-
ary Region (PBR). The PBR is the dimension of the per-
meable part of the endothelial glycocalyx which allows
the penetration of flowing red blood cells. Erythrocytes
usually have a limited access into an intact glycocalyx:
when this is compromised and starts losing its protective
capacity, its permeability increases, allowing circulating
cells to approach the luminal endothelial membrane more
closely. As a result, the dimension of the erythrocyte PBR
will increase [25].
Statistical analysis
Data were analyzed using GraphPad 5.0 program (GraphPad
Software, Inc, La Jolla, CA, USA). Data are presented as me-
dian [25th–75th percentiles]. Descriptive statistics were
computed for all study variables. A Kolmogorov-Smirnov
test was used, and stratified distribution plots were exam-
ined to verify the normality of distribution of continuous
variables. Nonparametric measures of comparison were
used when variables evaluated were not normally distrib-
uted. Differences between aPC and no-aPC group were
assessed using a chi-square, Fisher’s exact test, and unpaired
t-test or Mann–Whitney U test as appropriate. One-way
analysis of variance for repeated measures with Bonferroni
post test or Friedman test with Dunn’s post-test were used
to assess the evolution of microvascular perfusion in each
group. Relationships between variables were assessed by
Spearman’s correlation.Differences were considered significant at (two-sided)
p value < 0.05.
Results
Thirteen patients receiving aPC were included during the
study period. All the patients survived until the end of
aPC infusion. General characteristics, hemodynamic and
general management data are reported in Tables 1 and 2,
respectively.
As shown in Table 2, MAP, PaO2/FiO2 and BE were sig-
nificantly higher at T2 compared to T0, while lactate
levels, norepinephrine infusion rate and SOFA score were
significantly decreased.
Microcirculatory variables are shown in Table 3. All the
microvascular parameters improved over time, with signifi-
cant increases in MFI, MFIs (Figure 1A), TVD (Figure 1C),
PVD (Figure 1D) and PPV (Figure 1E) and a decrease in
the HI. A slight not significant decrease in PBR could be
noted over time (Figure 1F).
Nine patients with contraindications to aPC infusion
were monitored. All of them survived until the end of the
study protocol. No-aPC patients did not significantly differ
from aPC patients for age, gender, APACHE II score
(Table 1), SOFA score, hemodynamic parameters and
blood gas values (Table 2). Baseline microcirculatory vari-
ables were similar in no-aPC and aPC patients, except for
PVD which was significantly lower in the aPC-group (p <
0.05, Table 3). Hemodynamic, blood gases and the
Table 2 Hemodynamic and general management data
Bsln T1a (+24 h) T1b (+48 h) T1c (+72 h) T2 (6 h after aPC stop)
MAP (mmHg) aPC 78 (71–86) 88 (73–95) 91 (79–94) 89 (78–98) 97 (81–102) #
no-aPC 74 (65–85) 76 (67–87) 80 (79–88) 82 (72–87) 78 (70–86)
CI (L/min/m2) aPC 4.4 (3.5–5.3) 4.2 (3.5–5.4) 4.2 (3.9–4.3) 3.9 (3.4–4.7) 4.1 (3.5–4.4)
no-aPC 4.2 (3.4–4.3) 3.9 (3–4.7) 3.9 (3.7–4.5) 4 (3.4–4.3) 4 (3.5–4.2)
ITBVI (mL/m2) aPC 908 (750–1129) 878 (744–993) 863 (762–1083) 922 (799–1003) 855 (789–966)
no-aPC 1003 (945–1135) 997 (910–1071) 970 (860–1095) 918 (853–1050) 905 (847–992)
PaO2/FiO2 aPC 188 (135–291) 195 (161–296) 220 (158–286) 220 (193–253) 248 (219–301) ##
no-aPC 190 (189–287) 180 (173–251) 201 (184–238) 201 (156–266) 209 (162–325)
BE (mEq/L) aPC −1.9 (−7.5–1.2) 1.4 (−3.5–5.5) 3.5 (−0.3–7.2) # 5.8 (−1.4–8.2) ## 6.3 (−0.9–8.8) #
no-aPC 2.8 (−4.8–4.9) 4.3 (0.6–6) 5.3 (−1.1–8.3) 1.7 (−2.1–8.5) 1.6 (−2.8–8.6)
Lac (mmol/L) aPC 2.7 (1.5–3) 1.7 (1.4–2.8) 1.5 (1.4–2.4) 2 (1.3–2.4) 1.5 (1.1–1.9) # ††
no-aPC 2.8 (1.6–3.8) 2.3 (1.3–4.2) 1.6 (1.2–2.9) 1.2 (1–2.5) 1.5 (1.2–2.8)
Nora (μg/kg/min) aPC 0.29 (0.17–0.48) 0.27 (0.16–0.48) 0.22 (0.04–0.46) 0.21 (0–0.46) 0.03 (0–0.46) #
no-aPC 0.41 (0.16–0.51) 0.41 (0.19–0.63) 0.28 (0.1–0.66) 0.25 (0.11–0.56) 0.15 (0.11–0.52)
SOFA score aPC 11 (10–14) 11 (8–13) 10 (8–11) 9 (7–11) ## 8 (6–9) ### ††† **
no-aPC 10 (8–14) 12 (7–15) 11 (7–17) 11 (7–16) 11 (9–17) §
*p < 0.05, aPC group vs. no-aPC group at the same time point (** p < 0.01).
#p < 0.05, vs. T0 in the aPC-group (## p < 0.01; ### p < 0.0001).
§p < 0.05, vs. T0 in the no-aPC group.
†††p < 0.0001, vs. T1a in the aPC-group.
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during the whole study period. A significant increase in
the SOFA score was seen at T2 compared to T0 (Tables 2
and 3, Figure 1).
As shown in Table 2 and Figure 1, in aPC patients com-
pared to no-aPC the MFI was higher at T1c (p = 0.02) and
T2 (p = 0.001), MFIs, PVD, PPV and De Backer score were
higher (p = 0.03, p = 0.04, p = 0.04, p = 0.03 respectively)
and HI was lower (p = 0.01) at T2.
A significant correlation was found between MFIs and
MAP (r = 0.3, p < 0.01) but their changes over time were
not correlated. TVD, De Backer score and PVD were
negatively correlated with norepinephrine dose (r = −0.4,
p < 0.01; r = −0.3, p < 0.05; r = −0.2, p < 0.05, respectively).
No relationship was seen between changes in CI or in
ITBVI and changes in microcirculatory variables. The
SOFA score was negatively correlated with MFIs (r = −0.3,
p < 0.01), TVD (r = −0.5, p < 0.01) and PVD (r = −0.4, p <
0.01).
Discussion
The present study confirms that aPC treatment improves
the microcirculation in severe septic/septic shock patients.
This is in accordance with the conclusions of De Backer
et al. [18], who studied the effects of aPC on the microcir-
culation using orthogonal polarization spectral imaging
and evaluated changes in the De Backer score and PPV.
We tried to perform a more comprehensive analysis of the
microcirculation by calculating further parameters for ves-
sel density (TVD, PVD), microvascular perfusion (MFI,PPV) and flow distribution (HI). According to De Backer’s
findings, we found an improvement in the microvascular
density following aPC infusion, suggesting a recruitment
of capillaries which were not perfused before, and an in-
crease in the amount of continuously perfused vessels.
Additionally, the flow in the smaller vessels was improved
and more homogeneously distributed–as results from the
increase in MFIs and the decrease in the HI, respectively–
suggesting a benefit of aPC on the rheology of the micro-
circulation during sepsis.
Moreover, whereas we found a stable improvement in
the microcirculation, De Backer et al. had reported a
transient early worsening in microcirculatory variables
after aPC cessation, although they had neither indicated
significant differences towards previous days, nor found
a persistence of such a deterioration in the following
3 days. This discrepancy is not immediately clear to ex-
plain: indeed, aPC was infused at the same dose in both
studies; differences in patient baseline characteristics be-
tween the two studied cannot be excluded, although
baseline SOFA scores were similar in the two studies.
Differences in time point measurements may have
played a role: contrarily to De Backer, we only evaluated
the microcirculation every 24 hours and might have
missed a temporary slight alteration occurring during
the end of aPC infusion. Still, if such a transient deteri-
oration did occur, this might do nothing but confirm the
role of aPC in influencing the microvascular function:
indeed, it is logical to expect the end of the administra-
tion of a drug to be reflected by a transient instability at
Table 3 Microcirculatory data
Bsln T1a (+24 h) T1b (+48 h) T1c (+72 h) T2 (6 h after aPC stop)
MFI (AU) aPC 1.7 (1.5–2.3) 2.9 (2.5–3) ## 3 (2.5–3) # 2.9 (2.7–3) #* 3 (2.9–3) ###**
no-aPC 2.7 (1.5–3) 2.3 (2–3) 2.6 (1.7–2.9) 2.5 (2–2.6) 1.7 (1.6–2.8)
MFIs (AU) aPC 1.5 (1–2.3) 3 (2.8–3) ## 3 (2.5–3) # 3 (2.7–3) ## 3 (2.8–3) ## *
no-aPC 2.7 (2–3) 2.8 (2–3) 2.7 (2.1–3) 2.8 (2.4–3) 2 (1.6–3)
TVD (mm/mm2) aPC 11.1 (9.8–15) 14.5 (11.9–16) 14.3 (12–16.4) 14.1 (12.5–17.3) 16 (13.5–20) ###
no-aPC 14.9 (11.4–19.4) 16.2 (11.5–22.5) 14.2 (10–20.4) 16.6 (11.9–20.3) 15.4 (11.3–18.2)
PVD (mm/mm2) aPC 5.1 (3.2–7.7) * 10.7 (7–12.8) 7.4 (4.1–11.6) 11 (10–13.2) ## 11.6 (9.4–14.7) ## *
no-aPC 9.2 (5.9–17.8) 9.5 (5.1–20.6) 8.3 (7.1–15) 9 (6–17.9) 8.5 (4.3–10.6)
PPV (%) aPC 46 (32–55) 73 (59–83) 57 (37–82) 84 (66–93) ## 69 (65–85) *
no-aPC 72 (43–94) 60 (45–89) 71 (54–90) 53 (41–88) 56 (32–72)
De Backer score (n/mm) aPC 7.9 (5–9.7) 10.4 (6.2–11.1) 8.7 (5–11.3) 10.7 (7.8–13.8) 11.5 (8.4–14) *
no-aPC 10.5 (6.4–13.4) 8.2 (5.8–12) 8.9 (5.8–11.6) 8.3 (7.2–12.3) 7.3 (5.9–11.3)
HI (AU) aPC 0.5 (0.13–1.5) 0.25 (0–0.5) 0 (0–0.42) 0 (0–0.5) 0 (0–0) # *
no-aPC 0.07 (0–0.41) 0.07 (0–0.57) 0.07 (0–0.58) 0 (0–0.42) 0.5 (0–1.75)
PBR (μm) aPC 2.69 (2.11–3.11) 2.53 (2.36–2.73) 2.61 (2.46–2.79) 2.62 (2.33–2.81) 2.52 (2.40–2.65)
no-aPC 2.94 (2.65–3.08) 2.60 (2.54–2.84) 2.76 (2.56–2.84) 2.63 (2.43–3.00) 2.65 (2.61–2.73)
#p < 0.05, vs. T0 in the aPC-group (## p < 0.01; ### p < 0.0001).
*p < 0.05, aPC group vs. no-aPC group at the same time point (**p < 0.01).
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raw data, the PPV seemed to slightly decrease after aPC
cessation, even if the difference towards previous time
points was not significant.
Data for this study had been collected before the publica-
tion of the PROWESS SHOCK trial and the withdrawal of
aPC from the market. However, discrepancies between
PROWESS and PROWESS SHOCK trials are still a matter
of concern [26]. Several experimental evidences support the
beneficial effect of aPC on the microcirculation [14-17]. In
an experimental model of sepsis, Marechal et al. showed that
aPC administration was able to preserve either microvascular
perfusion and glycocalyx integrity [13]. Nevertheless, in our
study the microvascular recovery seems not to be related to
a glycocalyx restoration, although a slight even if not signifi-
cant PBR decrease was found during aPC infusion.
A significant decrease in blood lactate and an increase
in BE were seen during aPC treatment, which may reflect
an improved tissue oxygen uptake. This is consistent with
our previous findings: using near infrared spectroscopy,
we demonstrated that aPC infusion may increase tissue
oxygenation and microvascular reactivity in severely septic
patients, leading to an improved cellular metabolism [27].
MAP also increased after aPC administration. Neverthe-
less, this does not seem to be the reason for the micro-
vascular improvement, since either we and De Backer
found no relationship between changes in MAP and the
improvement in MFIs. Moreover, CI and ITBVI did not
change in aPC- nor in no-aPC patients and were not cor-
related to microvascular variables, according to previous
evidences [28,29]. We agree with De Backer in ratherrelating the increase in MAP to an effect of a better micro-
vascular tone. Indeed, many experimental studies demon-
strated that aPC can protect the microcirculation from
endotoxic shock thanks to its anti-inflammatory properties
[15,30-32] and the rise in MAP can be reasonably explained
by its ability to inhibit the iNOS, thereby preventing the ar-
teriolar vasodilation [12].
The case-crossover analysis, in which each patient served
as his/her own control, is a major limitation of our study.
We cannot be sure that the microvascular improvement
depended on different treatments or the independent evo-
lution in the patient’s condition rather than aPC infusion.
We monitored 9 severe sepsis/septic shock patients
who did not receive aPC because of contraindications.
The fact that these patients did not show any improve-
ment in the microcirculation over time would suggest
that aPC infusion can really exert a beneficial effect on
microvascular perfusion. However, beyond the lack of
differences in general characteristics and the collected
baseline clinical data, these patients were different from
aPC-patients by definition and the comparison between
them cannot provide any conclusion. As a major limita-
tion, our analysis is lacking of a real control group with
patients adequately matched to those receiving aPC,
which would allow to reliably discriminate the effects of
aPC on the microcirculation by controlling for possible
confounding factors. However, the case crossover design
was required for ethical reasons.
A further limitation of our study is that many factors
were not considered which might have independently af-
fected the microcirculation. Moreover, the sample was
Figure 1 Microcirculatory variables: aPC-group vs. no-aPC group. (a) Microvascular Flow Index for small vessels; (b) De Backer score; (c) Total
ll Vessel Density, (d) Perfused Vessel Density; (e) Proportion of Perfused Vessels; (f) Perfused Boundary Region. # p < 0.05, vs. T0 in the aPC-group
(## p < 0.01; ### p < 0.0001). * p < 0.05, aPC-group vs. aPC-group at the same time point.
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confounders.
The ability to improve the microcirculation would be of
major importance since the persistence of microvascular
alterations during septic shock proved to be associated
with the occurrence of organ failures and mortality [28].
In our cohort, microvascular flow and density negatively
correlated with norepinephrine requirement and SOFAscore. Unfortunately, our study was not designed to look
at mortality. Therefore, the relation between aPC treat-
ment and outcome could not be investigated, nor was it
possible to reliably test an association between the micro-
vascular improvement and survival. As a limitation, our
data do not allow to support that an aPC-induced im-
provement in microvascular perfusion may eventually re-
sult in lower risk of mortality.
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The present study supports a role of aPC treatment in
improving the microvascular perfusion in severe sepsis/
septic shock patients. The relationship between the aPC-
induced microvascular improvement and the outcome is
still to be demonstrated.
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